Grossman - Figure 11
BA06 30894: Trial of CMV in Muscle-invasive Bladder Cancer
FIG. 11: This Figure shows the results of an international study in almost 1000 patients with muscle-invasive bladder cancer that explored neoadjuvant chemotherapy and definitive treatment (BA06 30894).[3,4] The patients in this trial were randomized to either 3 cycles of CMV (cisplatin, methotrexate, vinblastine) or no CMV, and, unlike SWOG 8710,[2] all patients had had prior treatment with cystectomy and/or radiotherapy. Similar to SWOG 8710, the pathologic complete response rate was 33% in the patients randomized to CMV vs 12% in those who did not receive CMV.[3] The long-term results, reported for a median follow-up of 8 years, showed a 6% increase in absolute survival at 10 years with a significant 16% reduction in the risk of death.[4]
References
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859−66 https://doi.org/10.1056/NEJMoa022148
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533−40 https://doi.org/10.1016/S0140-6736(99)02292-8
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group; Griffiths G, Hall R, Sylvester R, et al. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171−7 https://doi.org/10.1200/JCO.2010.32.3139
